Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Chesov (Chisinau, Republic of Moldova), J. Heyckendorf (Borstel, Germany), M. Reiman (Borstel, Germany), S. Alexandru (Chisinau, Republic of Moldova), A. Donica (Chisinau, Republic of Moldova), E. Chesov (Chisinau, Republic of Moldova), V. Crudu (Chisinau, Republic of Moldova), V. Botnaru (Chisinau, Republic of Moldova), C. Lange (Borstel, Germany). Treatment outcome in patients with MDR-TB treated with bedaquiline containing regimens, Republic of Moldova. 474

Member's Comments

No comment yet.

Related content which might interest you: Treatment outcome of multi-drug resistant tuberculosis in the Republic of Moldova Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019 Year: 2019 Characteristics and treatment outcome of MDR-TB in the Czech Republic Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Experience of treatment Pre-XDR and XDR-TB/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova Source: Eur Respir J, 50 (4) 1701340; 10.1183/13993003.01340-2017 Year: 2017 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Treatment outcomes of the use of moxifloxacin in management of patients with XDR-TB in Tomsk Oblast of the Russian Federation Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Analysis of the cost-effectiveness of monotherapy versus fixed dose combination treatment of asthma in Republic of Moldova Source: Annual Congress 2013 –Asthma at the bedside Year: 2013 Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Outcomes of MDR cases in Iasi county, Romania Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015